The combined application of Annexin A2 and t-PA decreased the effective thrombolytic dose of tPA, reduced hemorrhage and brain infarction, and prolonged the reperfusion time window for stroke (Zhu et al., 2010; Jiang et al., 2015). The gene discussed is ANXA2; the disease is brain infarction.